This is an AMP page which is for mobile devices.
Link your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
home / articles / DTIL - Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today? | Benzinga
TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S. net product sales for Q4 and FY23.
TGTX expects BRIUMVI U.S. net product revenue of around $40 million for Q4 and $89 million for FY23.
The company projects a year-end 2023 cash position of about $215 million.
Outlook: TGTX sees BRIUMVI U.S. net product revenue of $41 million-$46 million in Q1 and $220 ...
| Company Name: | Precision BioSciences Inc. |
| Stock Symbol: | DTIL |
| Market: | NYSE |
| Website: | precisionbiosciences.com |
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by Benzinga via Quote Media. Read our full disclaimer.